Literature DB >> 18653335

The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues.

D Gomika Udugamasooriya1, Geoff Dunham, Caroline Ritchie, Rolf A Brekken, Thomas Kodadek.   

Abstract

Here we identify the pharmacophore in a peptoid that antagonizes Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) in vitro and in vivo. Only three of the side chains in the peptoid are required for activity. Surprisingly, however, main chain atoms also form critical interactions with the receptor.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18653335      PMCID： PMC2593102          DOI： 10.1016/j.bmcl.2008.07.023

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  14 in total

Review 1.  Peptide-based molecules in angiogenesis.

Authors:  Luca Domenico D'Andrea; Annarita Del Gatto; Carlo Pedone; Ettore Benedetti
Journal:  Chem Biol Drug Des       Date:  2006-02       Impact factor: 2.817

2.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

Authors:  H P Gerber; J Kowalski; D Sherman; D A Eberhard; N Ferrara
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

Review 3.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

4.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

Authors:  R A Brekken; J P Overholser; V A Stastny; J Waltenberger; J D Minna; P E Thorpe
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

Review 5.  Antiangiogenic agents.

Authors:  W D Klohs; J M Hamby
Journal:  Curr Opin Biotechnol       Date:  1999-12       Impact factor: 9.740

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

7.  A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity.

Authors:  D Gomika Udugamasooriya; Sean P Dineen; Rolf A Brekken; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2008-04-02       Impact factor: 15.419

8.  The molecular basis of virus crossreactivity and neutralisation after immunisation with optimised chimeric peptides mimicking a putative helical epitope of the measles virus hemagglutinin protein.

Authors:  K C El Kasmi; D Theisen; N H Brons; C P Muller
Journal:  Mol Immunol       Date:  1998-10       Impact factor: 4.407

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 10.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871
View more
  14 in total

1.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

Review 2.  Synthetic receptors with antibody-like binding affinities.

Authors:  Thomas Kodadek
Journal:  Curr Opin Chem Biol       Date:  2010-07-30       Impact factor: 8.822

3.  Identification of the minimum pharmacophore of lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1D1.

Authors:  Jaspal Singh; Satya Prakash Shukla; Tanvi J Desai; D Gomika Udugamasooriya
Journal:  Bioorg Med Chem       Date:  2016-07-21       Impact factor: 3.641

4.  On-bead combinatorial synthesis and imaging of chemical exchange saturation transfer magnetic resonance imaging agents to identify factors that influence water exchange.

Authors:  Roberta Napolitano; Todd C Soesbe; Luis M De León-Rodríguez; A Dean Sherry; D Gomika Udugamasooriya
Journal:  J Am Chem Soc       Date:  2011-07-27       Impact factor: 15.419

5.  Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

Authors:  Christina L Roland; Kristi D Lynn; Jason E Toombs; Sean P Dineen; D Gomika Udugamasooriya; Rolf A Brekken
Journal:  PLoS One       Date:  2009-11-03       Impact factor: 3.240

6.  GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.

Authors:  Kristi D Lynn; D Gomika Udugamasooriya; Christina L Roland; Diego H Castrillon; Thomas J Kodadek; Rolf A Brekken
Journal:  BMC Cancer       Date:  2010-07-30       Impact factor: 4.430

7.  Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells.

Authors:  Jaya M Matharage; John D Minna; Rolf A Brekken; D Gomika Udugamasooriya
Journal:  ACS Chem Biol       Date:  2015-10-28       Impact factor: 5.100

8.  On-Bead Two-Color (OBTC) Cell Screen for Direct Identification of Highly Selective Cell Surface Receptor Ligands.

Authors:  D Gomika Udugamasooriya; Thomas Kodadek
Journal:  Curr Protoc Chem Biol       Date:  2012-03-01

9.  Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression.

Authors:  Guiyang Hao; Asghar Hajibeigi; Luis M De León-Rodríguez; Orhan K Oz; Xiankai Sun
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-08-01

Review 10.  Tumor-targeting peptides from combinatorial libraries.

Authors:  Ruiwu Liu; Xiaocen Li; Wenwu Xiao; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2016-05-19       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.